Status:
ACTIVE_NOT_RECRUITING
Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.
Detailed Description
In recent years, next generation sequencing has revealed the genomic landscape of lymphoid disorders and identified mutations that have improved our understanding of their pathogenesis. It has also re...
Eligibility Criteria
Inclusion
- Chronic, mature clonal B-cell malignancy that is not assignable to a specific WHO category by current technology (see flowchart in section below).
Exclusion
- Non-clonal B-cell proliferation.
- High grade and/or immature clonal B-cell malignancy.
- Bone marrow samples with less than 20% infiltration will be excluded
- Samples from patients with a known classifiable chronic B-LPD based on lymph node biopsy for e.g. staging bone marrow samples on a patient with marginal zone lymphoma. If a definitive diagnosis is established on a subsequent lymph node biopsy, patient will remain on study and this will be correlated with NGS findings.
- Patient unable to provide consent for tumour and germ line samples.
Key Trial Info
Start Date :
August 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2026
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT03344809
Start Date
August 1 2016
End Date
May 1 2026
Last Update
April 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT